<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1702" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="858" end="861"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="863" end="866"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="868" end="871"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="878" end="888"/>
    <type:OSMean xmi:id="29" sofa="6" begin="904" end="905"/>
    <type:OSMean xmi:id="33" sofa="6" begin="907" end="909"/>
    <type:OSMean xmi:id="37" sofa="6" begin="911" end="913"/>
    <type:OSMean xmi:id="41" sofa="6" begin="919" end="929"/>
    <type:ORR xmi:id="45" sofa="6" begin="973" end="975"/>
    <type:ORR xmi:id="49" sofa="6" begin="977" end="978"/>
    <type:ORR xmi:id="53" sofa="6" begin="980" end="981"/>
    <type:ORR xmi:id="57" sofa="6" begin="987" end="989"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: a(v) integrins are involved in angiogenesis and melanoma&#13;&#10;tumourigenesis. Intetumumab (CNTO 95) is a fully human anti-a(v)-integrin&#13;&#10;monoclonal antibody.&#13;&#10;METHODS: In a multicentre, randomised, phase II study, stage IV melanoma patients&#13;&#10;were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg&#13;&#10;m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab&#13;&#10;(n=33), or 5 mg kg(-1) intetumumab (n=32) q3w. The primary endpoint was&#13;&#10;progression-free survival (PFS). Secondary endpoints included overall survival&#13;&#10;(OS), objective response rate (ORR), adverse events, and pharmacokinetics.&#13;&#10;RESULTS: No statistically significant differences in efficacy were observed&#13;&#10;between groups. In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1)&#13;&#10;intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4,&#13;&#10;and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of&#13;&#10;complete+partial response was 10, 3, 6, and 0%. Nonlinear intetumumab&#13;&#10;pharmacokinetics and potential intetumumab-dacarbazine interactions were&#13;&#10;observed. Transient, asymptomatic, nonrecurring, grade 1-2, uveitic reactions&#13;&#10;that resolved spontaneously or with topical steroids were seen in 22-30% of&#13;&#10;intetumumab-treated patients. Low-grade infusion-reaction symptoms (headache,&#13;&#10;fatigue, nausea, vomiting, fever, chills) were observed, as expected, in 16-73%&#13;&#10;of dacarbazine-treated patients. No intetumumab-related myelosuppression,&#13;&#10;laboratory/electrocardiogram abnormalities, or deaths occurred.&#13;&#10;CONCLUSION: With its favourable safety profile and a nonsignificant trend towards&#13;&#10;improved OS, intetumumab merits further investigation in advanced melanoma."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33 37 41 45 49 53 57"/>
</xmi:XMI>
